PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma

por Michael B. Atkins, Suthee Rapisuwon, Arash Radfar, Kellie Gardner, Neil J. Shah, Geoffrey T. Gibney, Jacob Zaemes, Shelly Shand, David Swoboda, Vesna Petronic-Rosic, Michael J. Reilly, Waddah B. Al-Refaie
Publicado 2021

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

por Mariaelena Pierobon, Johann De Bono, Ruth Riisnaes, Giuseppe Giaccone, Matthew Blackburn, Lance Liotta, Vienna Ludovini, Neil J Shah, Giuseppina Improta, Antonella Ravaggi, Niven Mehra, Angelo Sidoni, Elisa Baldelli, K Alex Hodge, Guido Bellezza, Guido Gambara, Martina Mandarano, Chamodya Ruhunusiri, Bryant Dunetz, Maysa Abu-Khalaf, Julia Wulfkuhle, Rosa I Gallagher, Franco Odicino, Maria Isabella Sereni, Angela Zupa, Perry Demsko, Lucio Crino', Emanuel F Petricoin
Publicado 2021